{
    "clinical_study": {
        "@rank": "166521", 
        "arm_group": [
            {
                "arm_group_label": "Sitagliptin", 
                "arm_group_type": "Active Comparator", 
                "description": "Substance:\t\t\tSitagliptin phosphate 1H2O Pharmaceutical form:\t\ttablets Source:\t\t\tMSD SHARP & DOHME GMBH, Doses:\t\t\t\t100 mg, Route of administration:\tp.o. as a tablet"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Substance:\t\t\tPlacebo (sitagliptin) Pharmaceutical form:\t\ttablets Source:\tMSD SHARP & DOHME GMBH Doses:\t\t\t\t- Route of administration:\tp.o. as tablets"
            }
        ], 
        "brief_summary": {
            "textblock": "Objectives: To quantify differences in control of glycemia (primary objective) and the\n      secretion of endogenous incretin hormones (secondary objective) comparing sitagliptin or\n      placebo added to pre-existing therapy with liraglutide and metformin"
        }, 
        "brief_title": "Antidiabetic Effects of Adding a DPP-4 Inhibitor (Sitagliptin) to Pre-Existing Treatment With an Incretin Mimetic (Liraglutide) in Patients With Type 2 Diabetes Treated With Metformin", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a double blind, controlled, cross-over comparison of adding sitagliptin (or placebo)\n      to pre-existing metformin+liraglutide therapy. Patients with type 2 diabetes mellitus (T2DM)\n      on pre-existing treatment with metformin (\u2265 1500 mg/d) monotherapy or metformin plus\n      liraglutide (1.2 mg/d) will be studied. Patients on metformin monotherapy will, after\n      screening and randomization, enter a run-in period of 2 weeks with the additional treatment\n      of liraglutide (0.6 mg/d for 1 week followed by 1.2 mg/d for another week).  At the end of\n      this 2 weeks therapy, a mixed meal challenge will take place, with the assessment of glucose\n      and hormone responses (insulin, C-peptide, glucagon, GLP-1, GIP) and gastric emptying as\n      measured by 13C-octanoate breath tests. Prior to the meal tests, liraglutide will be\n      administered at a dose of 1.2 mg per injection, which is the recommended dose for treatment.\n      Sitagliptin will be used at a dose of 100 mg, which is recommended for clinical use."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Signed and dated written informed consent obtained before any study-related\n             activities\n\n          2. Male and female subjects with a diagnosis of type 2 diabetes mellitus according to\n             ADA criteria at least 4 months prior to screening\n\n          3. Medical history without major pathology (with the exception of type 2 diabetes) as\n             judged by the investigator\n\n          4. On a stable regimen of metformin for at least 1 month and liraglutide 1.2 mg for at\n             least 1 week at the time-point of randomisation.\n\n          5. Aged between 25 and 75 years, both inclusive\n\n          6. Body mass index (BMI) between 22 and 40kg/m2, both inclusive\n\n          7. HbA1c \u2265 6.5 and \u2264 8.5% (\u2265 7.0 and \u2264 8.5% for patients without previous liraglutide\n             treatment)\n\n          8. Female must be post-menopausal, surgically sterilized or practicing an effective\n             birth control\n\n        Exclusion criteria\n\n          1. Subjects with type 1 diabetes, maturity onset diabetes of the young (MODY) or\n             secondary forms of diabetes such as due to pancreatitis\n\n          2. Current or previous treatment with insulin therapy (except for treatment at diabetes'\n             diagnosis, within a clinical trial, for surgical procedures or during an acute\n             illness, and no insulin administration within the 6 months before screening)\n\n          3. Treatment with any hypoglycaemic medication other than metformin and liraglutide\n             within one month prior to screening\n\n          4. Subjects with known diabetic gastroparesis and / or prokinetic therapy\n\n          5. Subjects that underwent surgery of the upper gastrointestinal tract\n\n          6. Women who are pregnant, intending to become pregnant during the study period,\n             currently lactating females, or women of child-bearing potential not using highly\n             effective, medically approved birth control methods\n\n          7. Subjects with any severe medical or surgical history of conditions likely to confound\n             study assessments or study endpoints, for example but not limited to\n             haemoglobinopathies, inflammatory bowel disease, cystic fibrosis, bariatric surgery\n             and/or any surgery shortening the intestine, history of lactose intolerance,\n             lactose- or glucose-galactose-malabsorption\n\n          8. Subjects with a suspicion of medullary thyroid cancer or a multiple endocrine\n             neoplasia\n\n          9. Subjects with a personal or family history of medullar thyroid cancer or a multiple\n             endocrine neoplasia\n\n         10. Serious and/or unstable coronary heart disease (unstable angina, myocardial\n             infarction within the preceding 6 months), congestive heart failure of New York Heart\n             Association Class III or worse (severe limitation of physical activity; physical\n             activity of low intensity resulting in fatigue, palpitation, or dyspnoea),\n             second/third degree heart block, superior vena cava syndrome, uncontrolled\n             hypertension, history of congenital QT-syndrome within family, history of stroke\n             (within the preceding 6 months) or serious peripheral vascular disease\n\n         11. History of arrhythmia (multifocal premature ventricular contractions, bigeminy,\n             trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) that is\n             symptomatic or requires treatment (grade 3), left bundle branch block, or\n             asymptomatic sustained ventricular tachycardia are not allowed\n\n         12. Marked diabetic complications: severe autonomic or sensory neuropathy including\n             previously diagnosed gastroparesis; proliferative retinopathy\n\n         13. Any respiratory disease leading to respiratory insufficiency and/or depression\n             including but not limited to clinically significant: bronchial asthma, chronic\n             obstructive pulmonary disease, that might impact to the breath test, as judged by the\n             investigator\n\n         14. Clinically significant vital signs including known bradycardia with pulse rate <\n             50/min or 12-lead ECG findings including QTc > 450 msec for males or QTc > 470 msec\n             for women\n\n         15. Clinically significant abnormal haematology, biochemistry, lipids, or urinalysis or\n             coagulation screening tests, as judged by the Investigator\n\n         16. Moderate or severe renal dysfunction defined as an estimated creatinine clearance\n             (MDRD equation) GFR <50 ml/min.\n\n         17. Clinical or laboratory evidence of hepatic dysfunction or disease; laboratory\n             evidence defined as any of the following parameters: alkaline  phosphatase, ALT, AST\n             or bilirubin > 3x ULN. Isolated mild rise in bilirubin considered to be due to\n             Gilbert's condition is allowed\n\n         18. Uncontrolled high blood pressure (DBP > 95 mmHg and/or SBP > 160 mmHg), unless\n             clearly documented to be white-coat hypertension\n\n         19. History of any psychiatric condition that might impair the subject's ability to\n             understand or to comply with the requirements of the study or to provide informed\n             consent\n\n         20. History of relevant drug and/or food allergies or a history of severe anaphylactic\n             reaction\n\n         21. Currently active or history of alcohol abuse (defined as an intake of more than 24\n             units of alcohol per week; one unit of alcohol equals approximately 250 mL of beer,\n             100 mL of wine or 35 mL of spirits) or drug addiction (including soft drugs like\n             cannabis products)\n\n         22. Use of concomitant medication which would be likely to interact with metformin,\n             sitagliptin or liraglutide (according to the subject information leaflet).\n             Participation in another clinical trial within the 3 months preceding screening or\n             5-half-lives of drug studied, whichever is longer, prior to study medication\n             administration\n\n         23. Malignancy within 5 years of study start, except for successfully treated local basal\n             cell carcinomas\n\n         24. Subjects known to be positive for Hepatitis B surface antigen or Hepatitis C\n             antibodies (or diagnosed with active hepatitis according to local practice)\n\n         25. Subject who has donated or lost more than 500 mL blood within 3 months prior to\n             screening and has an Hb < 14 g/dl at screening\n\n         26. History of hypersensitivity to the study medication or any of the excipients or to\n             medicinal products with similar chemical structures\n\n         27. Veins unsuitable for repeated venipuncture"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01937598", 
            "org_study_id": "120-0569-DZBL-2012", 
            "secondary_id": "2013-001764-35"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sitagliptin", 
                "intervention_name": "Sitagliptin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sitagliptin", 
                    "Placebo"
                ], 
                "description": "Subjects will be instructed to consume the mixed meal test within 20 minutes. The exact start and stop time of the mixed meal test consumption will be recorded in the CRF. The mixed meal test procedures will be identical for all subjects randomised in the study. To detect the plasma glucose excursion after mixed meal test, plasma glucose will be closely monitored", 
                "intervention_name": "Mixed meal test", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Sitagliptin", 
                    "Placebo"
                ], 
                "description": "Patients on metformin monotherapy will, after screening and randomization, enter a run-in period of 2 weeks with the additional treatment of liraglutide (0.6 mg/d for 1 week followed by 1.2 mg/d for another week) that will be continued for the entire duration of the study.", 
                "intervention_name": "Liraglutide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Liraglutide", 
                    "(Source Victoza Prescribing Information, issued April 6, 2012, Version 3)"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Sitagliptin", 
                "Hypoglycemic Agents", 
                "Metformin", 
                "Glucagon-Like Peptide 1", 
                "Incretins", 
                "Dipeptidyl-Peptidase IV Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Incretin, DPP-4 inhibitor", 
        "lastchanged_date": "September 4, 2013", 
        "location": {
            "contact": {
                "email": "nauck@diabeteszentrum.de", 
                "last_name": "Michael A. Nauck"
            }, 
            "facility": {
                "address": {
                    "city": "Bad Lauterberg", 
                    "country": "Germany", 
                    "zip": "37431"
                }, 
                "name": "Diabeteszentrum Bad Lauterberg"
            }, 
            "investigator": {
                "last_name": "Oleg Baranov", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Antidiabetic Effects of Adding a DPP-4 Inhibitor (Sitagliptin) to Pre-Existing Treatment With an Incretin Mimetic (Liraglutide) in Patients With Type 2 Diabetes Treated With Metformin", 
        "overall_contact": {
            "email": "nauck@diabeteszentrum.de", 
            "last_name": "Michael A. Nauck, Prof. Dr. med."
        }, 
        "overall_official": {
            "affiliation": "Diabeteszentrum Bad Lauterberg", 
            "last_name": "Michael A. Nauck, Prof. Dr. med.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Ethics Commission", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Incremental area under the plasma glucose (BG) concentration-time profile (AUC) immediately before to 300 min after a mixed meal test. In addition, the time course of BG values will be analysed with an ANCOVA model for repeated measurements with placebo baseline values as covariate.", 
            "measure": "Incremental area under the plasma glucose (BG) concentration-time profile (AUC)", 
            "safety_issue": "No", 
            "time_frame": "Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01937598"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Diabeteszentrum Bad Lauterberg im Harz", 
            "investigator_full_name": "Michael A. Nauck", 
            "investigator_title": "Prof. Dr. med.", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Incremental AUC from 0 to 300 min", 
                "measure": "AUC plasma glucose", 
                "safety_issue": "No", 
                "time_frame": "Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)"
            }, 
            {
                "measure": "AUC insulin", 
                "safety_issue": "No", 
                "time_frame": "Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)"
            }, 
            {
                "measure": "AUC C-peptide", 
                "safety_issue": "No", 
                "time_frame": "Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)"
            }, 
            {
                "measure": "AUC glucagon", 
                "safety_issue": "No", 
                "time_frame": "Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)"
            }, 
            {
                "measure": "AUC total GLP-1", 
                "safety_issue": "No", 
                "time_frame": "Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)"
            }, 
            {
                "measure": "AUC total GIP", 
                "safety_issue": "No", 
                "time_frame": "Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)"
            }, 
            {
                "measure": "AUC active GLP-1", 
                "safety_issue": "No", 
                "time_frame": "Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)"
            }, 
            {
                "measure": "AUC active GIP", 
                "safety_issue": "No", 
                "time_frame": "Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)"
            }, 
            {
                "description": "velocity of gastric emptying as determined through 13C-breath test with t\u00bd, lag time, gastric emptying coefficient and time course as main outcome parameters.", 
                "measure": "Velocity of gastric emptying", 
                "safety_issue": "No", 
                "time_frame": "Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)"
            }, 
            {
                "measure": "plasma glucose concentration 120 min after starting the meal;", 
                "safety_issue": "No", 
                "time_frame": "Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)"
            }
        ], 
        "source": "Diabeteszentrum Bad Lauterberg im Harz", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Michael A. Nauck", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}